Trial Profile
Open Randomized Study to Assess the Evolution of Plasma Lipid Profile by Lipidomic in Patients Infected With Human Immunodeficiency Virus (HIV-1) With Viral Suppression That Change Atripla to Eviplera Compared to Continue With Atripla
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 17 Jun 2017
Price :
$35
*
At a glance
- Drugs Emtricitabine/rilpivirine/tenofovir disoproxil fumarate (Primary) ; Efavirenz/emtricitabine/tenofovir-disoproxil-fumarate
- Indications HIV-1 infections
- Focus Therapeutic Use
- 15 Mar 2017 Status changed from active, no longer recruiting to completed.
- 06 Jun 2016 Planned End Date changed from 1 Sep 2016 to 1 Oct 2016.
- 06 Jun 2016 Planned primary completion date changed from 1 Jun 2016 to 1 Oct 2016.